(AOF) – Abivax held its Annual Ordinary and Extraordinary General Meeting on June 9th. The resolutions presented by the Board of Directors were adopted and in particular, the approval of the financial statements for the year ended December 31, 2021, the compensation policy applicable to the Chairman of the Board of Directors, the Chief Executive Officer and the directors , as well as the delegations granted to the Board of Directors in financial matters.
The Meeting also approved the renewal of the directorships of Jean-Jacques Bertrand, Pr. Carol L. Brosgart, MD, Joy Amundson and Sofinnova Partners.
AOF – LEARN MORE
Oncology supports laboratory performance
Oncology generated $163 billion in revenue in 2021 (out of an industry total of $613 billion), up 11.9%, according to GlobalData. Its average annual growth has reached 15.4% over the past twenty years. This segment, which is increasingly competitive, is dominated by a few heavyweights such as MSD (Merck & Co. Inc), Roche, BMS
.
L
‘
immuno-oncology, the specialty that has been driving this market for ten years, supports research. GlobalData estimates that this segment could reach 180 billion in 2026. The major players are looking to strengthen themselves in this niche. Pfizer recently acquired Canadian biotech Trillium Therapeutics for $2.3 billion. Following this operation, the American group got hold of two promising molecules in the treatment of blood cancer.